ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing [Seeking Alpha]
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Seeking Alpha
Barbara Klencke as the permanent Chief Medical Officer, following her interim leadership since September 2025. Lettmann stated, “We're beyond fortunate to add Barb during this critical Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights ALX Oncology is advancing both programs on schedule, expanding key trials, and targeting pivotal trial readiness by end of next year, supported by strong biomarker-driven response rates and successful financing. The company strengthened its balance sheet with a $150 million financing, reduced its quarterly net loss, and has enough cash to fund operations through the first half of 2028. Management is closely monitoring safety for ALX2004 and optimizing CD47 biomarker analysis, leveraging literature and robust protocols to manage risks and enhance trial reliability. More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update [Yahoo! Finance]Yahoo! Finance
- ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones [Seeking Alpha]Seeking Alpha
- ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
ALXO
Earnings
- 2/27/26 - Miss
ALXO
Sec Filings
- 3/5/26 - Form 4
- 3/5/26 - Form 3
- 2/27/26 - Form 8-K
- ALXO's page on the SEC website